journal
MENU ▼
Read by QxMD icon Read
search

Advances in Therapy

journal
https://www.readbyqxmd.com/read/28108895/chronic-wound-healing-a-review-of-current-management-and-treatments
#1
REVIEW
George Han, Roger Ceilley
Wound healing is a complex, highly regulated process that is critical in maintaining the barrier function of skin. With numerous disease processes, the cascade of events involved in wound healing can be affected, resulting in chronic, non-healing wounds that subject the patient to significant discomfort and distress while draining the medical system of an enormous amount of resources. The healing of a superficial wound requires many factors to work in concert, and wound dressings and treatments have evolved considerably to address possible barriers to wound healing, ranging from infection to hypoxia...
January 21, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28108894/behavior-modification-a-patient-and-physician-s-perspective
#2
LETTER
Elizabeth Swanson, Craig Primack
This article, co-authored by a patient affected by obesity and an obesity medicine specialist, discusses the patient's experience of living with the disease and using many different weight loss approaches until finding a lifestyle program that was appropriate for her metabolism. The physician discusses the scientific basis of insulin resistance, and why the chosen lifestyle program worked so well for this individual.
January 20, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28108893/comment-on-efficacy-and-treatment-costs-of-monotherapy-with-bdmards-in-the-treatment-of-rheumatoid-arthritis-in-patients-intolerant-to-or-inappropriate-to-continue-treatment-with-methotrexate
#3
LETTER
https://www.readbyqxmd.com/read/28083815/optimizing-the-use-of-linaclotide-in-patients-with-constipation-predominant-irritable-bowel-syndrome-an-expert-consensus-report
#4
REVIEW
Enrique Rey, Fermín Mearin, Javier Alcedo, Constanza Ciriza, Silvia Delgado-Aros, Teresa Freitas, Miguel Mascarenhas, Miguel Mínguez, Javier Santos, Jordi Serra
INTRODUCTION: Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by chronic or recurrent abdominal pain in association with defecation or a change in bowel habits. A predominant disorder of bowel habits, IBS is classified into three main subtypes: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D) and IBS alternating between constipation and diarrhea (IBS-M). Linaclotide is a first-in-class, oral, once-daily guanylate cyclase-C receptor agonist (GC-CA) that is licensed for the symptomatic treatment of moderate-to-severe IBS-C in adults...
January 12, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28078541/glucagon-like-peptide-1-receptor-agonist-glp-1ra-therapy-adherence-for-patients-with-type-2-diabetes-in-a-medicare-population
#5
Hiep Nguyen, Robert Dufour, Amanda Caldwell-Tarr
INTRODUCTION: Anti-diabetes medication regimen adherence is a clinical challenge in elderly patients with type 2 diabetes (T2D) and other comorbidities associated with aging. Glucagon-like peptide-1 receptor agonists (GLP-1RA) therapies such as exenatide once weekly (QW), exenatide twice daily (BID), and liraglutide once daily (QD) are an increasingly used class of drugs with proven efficacy and tolerability. Real-world evidence on adherence to GLP-1RAs in elderly or disabled patients is limited...
January 11, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28070862/pharmacokinetic-evaluation-of-once-weekly-and-once-monthly-buprenorphine-subcutaneous-injection-depots-cam2038-versus-intravenous-and-sublingual-buprenorphine-in-healthy-volunteers-under-naltrexone-blockade-an-open-label-phase-1-study
#6
Muna Albayaty, Margareta Linden, Håkan Olsson, Markus Johnsson, Kerstin Strandgården, Fredrik Tiberg
INTRODUCTION: CAM2038 q1w (once weekly) and q4w (once monthly) are investigational buprenorphine subcutaneous (SC) formulations based on FluidCrystal(®) injection depot technology. These two drug products are being developed for opioid dependence treatment, with a target for once-weekly and once-monthly SC dosing. The rationale for developing two products with different dosing frequencies is that treatment strategies/routines, and hence different treatment preferences, can vary between patients, different stages of opioid maintenance treatment, and countries...
January 9, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28070861/efficacy-and-safety-of-vedolizumab-in-ulcerative-colitis-and-crohn-s-disease-patients-stratified-by-age
#7
Vijay Yajnik, Nabeel Khan, Marla Dubinsky, Jeffrey Axler, Alexandra James, Brihad Abhyankar, Karen Lasch
INTRODUCTION: The efficacy and safety of vedolizumab, a gut-selective α4β7 integrin antibody, were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18-80 years. We investigated the efficacy and safety of vedolizumab in patients stratified by age from the GEMINI trials. METHODS: Safety and efficacy, including clinical response, clinical remission, and corticosteroid-free remission, at week 6 and/or 52 were determined post hoc in patients aged <35, 35 to <55, and ≥55 years...
January 9, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28054310/modulation-of-neuroinflammation-in-the-central-nervous-system-role-of-chemokines-and-sphingolipids
#8
REVIEW
Roberta Gualtierotti, Laura Guarnaccia, Matteo Beretta, Stefania E Navone, Rolando Campanella, Laura Riboni, Paolo Rampini, Giovanni Marfia
Neuroinflammation is a process involved in the pathogenesis of different disorders, both autoimmune, such as neuropsychiatric systemic lupus erythematosus, and degenerative, such as Alzheimer's and Parkinson's disease. In the central nervous system, the local milieu is tightly regulated by different mediators, among which are chemoattractant cytokines, also known as chemokines. These small molecules are able to modulate trafficking of immune cells in the course of nervous system development or in response to tissue damage, and different patterns of chemokine molecule and receptor expression have been described in several neuroinflammatory disorders...
January 4, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28054309/the-effect-of-evolving-strategies-in-the-surgical-management-of-organ-confined-prostate-cancer-comparison-of-data-from-2005-to-2014-in-a-multicenter-setting
#9
Margit Pohle, Ahmed Magheli, Tom Fischer, Carsten Kempkensteffen, Jonas Busch, Hannes Cash, Kurt Miller, Stefan Hinz
INTRODUCTION: The objective of this study was to evaluate changes of patient characteristics and surgical techniques in radical prostatectomy in Germany within the last decade. METHODS: Data from 44 German prostate cancer centers were included in the study. Patients' characteristics (age, initial PSA value), surgical techniques (open vs. minimally invasive approaches), perioperative parameters (operating time, rate of nerve-sparing (NS) radical prostatectomies (RPs), hospitalization time, catheter indwelling time, surgical margin status, number of dissected lymph nodes (LN)), and pathological findings (tumor stage, Gleason score) were analyzed...
January 4, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28044255/mavoglurant-augmentation-in-ocd-patients-resistant-to-selective-serotonin-reuptake-inhibitors-a-proof-of-concept-randomized-placebo-controlled-phase-2-study
#10
Daniel Rutrick, Dan J Stein, Ganesan Subramanian, Brian Smith, Maurizio Fava, Gregor Hasler, Jang-Ho Cha, Fabrizio Gasparini, Toni Donchev, Magdalena Ocwieja, Donald Johns, Baltazar Gomez-Mancilla
INTRODUCTION: To determine if mavoglurant (modified release) as an augmentation therapy to selective serotonin reuptake inhibitors (SSRIs) could have beneficial effects reducing Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score in patients with obsessive-compulsive disorder (OCD) resistant to SSRI treatment. METHODS: This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 2 study. Patients remained on their SSRI treatment and mavoglurant or placebo was added on...
January 2, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28028737/efficacy-of-testosterone-suppression-with-sustained-release-triptorelin-in-advanced-prostate-cancer
#11
Jürgen Breul, Eija Lundström, Daniela Purcea, Werner P Venetz, Patrick Cabri, Pascale Dutailly, Evan R Goldfischer
INTRODUCTION: Androgen deprivation therapy (ADT) is a mainstay of treatment against advanced prostate cancer (PC). As a treatment goal, suppression of plasma testosterone levels to <50 ng/dl has been established over decades. Evidence is growing though that suppression to even lower levels may add further clinical benefit. Therefore, we undertook a pooled retrospective analysis on the efficacy of 1-, 3-, and 6-month sustained-release (SR) formulations of the gonadotropin-releasing hormone (GnRH) agonist triptorelin to suppress serum testosterone concentrations beyond current standards...
December 27, 2016: Advances in Therapy
https://www.readbyqxmd.com/read/28004361/a-review-of-obinutuzumab-ga101-a-novel-type-ii-anti-cd20-monoclonal-antibody-for-the-treatment-of-patients-with-b-cell-malignancies
#12
REVIEW
Kensei Tobinai, Christian Klein, Naoko Oya, Günter Fingerle-Rowson
Obinutuzumab (GA101) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed to address the need for new therapeutics with improved efficacy in patients with lymphocytic leukemia and lymphoma of B-cell origin. Obinutuzumab has a distinct mode of action relative to type I anti-CD20 antibodies, such as rituximab, working primarily by inducing direct cell death and antibody-dependent cell-mediated cytotoxicity. Obinutuzumab is under investigation in a wide-ranging program of clinical trials in patients with B-cell malignancies...
December 21, 2016: Advances in Therapy
https://www.readbyqxmd.com/read/28000169/relative-efficacy-of-granulocyte-macrophage-colony-stimulating-factor-dacarbazine-and-glycoprotein-100-in-metastatic-melanoma-an-indirect-treatment-comparison
#13
Casey Quinn, Qiufei Ma, Amber Kudlac, Stephen Palmer, Beth Barber, Zhongyun Zhao
INTRODUCTION: Advances in the treatment of metastatic melanoma have been achieved in recent years: immunotherapies and targeted therapies have demonstrated survival benefits over older agents such as granulocyte-macrophage colony-stimulating factor (GM-CSF), dacarbazine, and glycoprotein peptide vaccine (gp100) in pivotal phase 3 trials. It is important to compare therapies to guide the treatment decision-making process, and establishing the relationship between older agents can strengthen the networks of evidence for newer therapies...
December 20, 2016: Advances in Therapy
https://www.readbyqxmd.com/read/28000168/caregiver-preference-and-treatment-compliance-in-patients-with-mild-to-moderate-alzheimer-s-disease-in-south-korea-recap-study-results
#14
Kang Joon Lee, Seong-Jin Cho, Byeong Chae Kim, Minseok Park, Jae-Hong Lee
INTRODUCTION: The aim of this study was to assess caregiver preference and treatment compliance with oral and transdermal medications in a "real-world" setting in patients with mild-to-moderate Alzheimer's disease (AD) in South Korea. METHODS: Real-world evaluation of compliance and preference in Alzheimer's disease treatment (RECAP) was a 24-week, multicenter, prospective, non-interventional study in patients with AD treated with oral or transdermal therapy. Here, we report data from patients living in South Korea...
December 20, 2016: Advances in Therapy
https://www.readbyqxmd.com/read/28000167/cost-effectiveness-of-different-strategies-for-the-prevention-of-venous-thromboembolism-after-total-hip-replacement-in-china
#15
Xiaoyu Yan, Xiaohua Gu, Zhenxing Xu, Houweng Lin, Bin Wu
INTRODUCTION: The aim of this study was to evaluate the cost-effectiveness of rivaroxaban and apixaban versus enoxaparin for the universal prophylaxis of venous thromboembolism (VTE) and associated long-term complications in Chinese patients after total hip replacement (THR). METHODS: A decision model, which included both acute VTE (represented as a decision tree) and the long-term complications of VTE (represented as a Markov model), was developed to assess the economic outcomes of the three prophylactic strategies for Chinese patients after THR...
December 20, 2016: Advances in Therapy
https://www.readbyqxmd.com/read/28000166/current-perspectives-on-the-use-of-anti-vegf-drugs-as-adjuvant-therapy-in-glaucoma
#16
REVIEW
Vanessa Andrés-Guerrero, Lucía Perucho-González, Julián García-Feijoo, Laura Morales-Fernández, Federico Saenz-Francés, Rocío Herrero-Vanrell, Luis Pablo Júlvez, Vicente Polo Llorens, José María Martínez-de-la-Casa, Anastasios-Georgios P Konstas
The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has demonstrated the utility of these therapies for the treatment of other ocular conditions characterized by elevated VEGF levels. In this article we review current perspectives on the use of anti-VEGF drugs as adjuvant therapy in the management of neovascular glaucoma (NVG)...
December 20, 2016: Advances in Therapy
https://www.readbyqxmd.com/read/28000165/patient-satisfaction-with-collection-of-patient-reported-outcome-measures-in-routine-care
#17
Pablo F Recinos, Cheryl J Dunphy, Nicolas Thompson, Jesse Schuschu, John L Urchek, Irene L Katzan
INTRODUCTION: Systematic collection of patient-reported outcome measures (PROMs) during ambulatory clinic visits can enhance communication between patient and provider, and provide the ability to evaluate outcomes of care. Little is known about patient satisfaction of PROM data collection in routine clinical care. To evaluate patient reaction to the routine collection of PROMs in the ambulatory setting. METHODS: Before all ambulatory clinic visits at our neurological institute, patients electronically complete health status questionnaires...
December 20, 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27981497/factors-affecting-canagliflozin-induced-transient-urine-volume-increase-in-patients-with-type-2-diabetes-mellitus
#18
Hiroyuki Tanaka, Kazuhiko Takano, Hiroaki Iijima, Hajime Kubo, Nobuko Maruyama, Toshio Hashimoto, Kenji Arakawa, Masanori Togo, Nobuya Inagaki, Kohei Kaku
INTRODUCTION: Sodium glucose co-transporter 2 (SGLT2) inhibitors exhibit diuretic activity, which is a possible mechanism underlying the cardiovascular benefit of these inhibitors. However, the osmotic diuresis-induced increase in urine volume, and the risk of dehydration have been of concern with SGLT2 inhibitor treatment. This study aimed to investigate the mechanism underlying SGLT2 inhibitor canagliflozin-induced diuresis in Japanese type 2 diabetes mellitus (T2DM) patients. METHODS: Thirteen T2DM patients received a daily oral dose of 100 mg canagliflozin before breakfast for 6 days...
December 15, 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27981496/a-review-of-clinical-practice-guidelines-for-the-management-of-hypertriglyceridemia-a-focus-on-high-dose-omega-3-fatty-acids
#19
REVIEW
Dean G Karalis
Cardiovascular (CV) disease remains the leading cause of preventable death in the US. Hyperlipidemia is a major modifiable risk factor for CV disease, and after numerous clinical trials have demonstrated that reductions in low-density lipoprotein (LDL) cholesterol with statin therapy can prevent major adverse CV events, statins have emerged as the drug of choice to lower LDL cholesterol and reduce CV risk. However, some statin-treated patients remain at high residual risk of CV events despite achieving low LDL cholesterol levels, especially if their triglyceride (TG) levels are elevated or their high-density lipoprotein (HDL) cholesterol levels low...
December 15, 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27981495/chronic-obstructive-pulmonary-disease-individualized-therapy-tailored-approach-to-symptom-management
#20
REVIEW
Dave Singh, Marc Miravitlles, Claus Vogelmeier
Chronic obstructive pulmonary disease (COPD) is associated with high morbidity and mortality. COPD is typified by persistent, progressive airflow limitation and a range of respiratory and systemic symptoms such as breathlessness, coughing, wheezing, depression, anxiety, general fatigue, and sleeping difficulties. Despite receiving treatment for COPD, many patients suffer from regular symptoms that affect their daily lives and lead to increased morbidity. These symptoms vary in severity, frequency, and type, and can occur at any time throughout the 24-h day, with over half of patients with COPD experiencing symptoms in the morning, during the day, and at nighttime...
December 15, 2016: Advances in Therapy
journal
journal
29381
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"